Emergency chest pain assessment

General considerations
Most chest pain algorithms aim to exclude ACSs. Initial and contin uous assessment of vital signs (blood pressure (BP), pulse, cardiac monitoring and oxygen saturations) should be standard care. If the patient is tachypnoeic or has oxygen saturations <94%, supplemental oxygen should be administered. Pain should be managed with appropriate analgesia, preferably intravenous opioids such as morphine. A focused history, thorough physical examination, meti culous review of a 12lead electrocardiogram (ECG) and appro priately timed measurement of cardiac biomarkers are the key com ponents of an effective chest pain assessment.
History
The history is the most useful component when evaluating chest pain, as both normal and abnormal investigations (such as the ECG, cardiac biomarkers and chest radiograph (CXR)) must be interpreted in the context of the patient's history.
The mnemonic SOCRATES (Site Onset Character Radiation Asso ciation Time Exacerbating/relieving factor and Severity) helps differen tiate cardiac v. noncardiac (respiratory, gastric or musculoskeletal) pain. Features that make a diagnosis of ACS likely include: central (retro sternal) location; sudden or acute onset; heavy or burning sensation with radiation to the arm or jaw; associated dyspnoea, nausea or sweating; duration >15 minutes; relief of symptoms by nitrates; worsening of symptoms by activity; chest or leftarm discomfort that is the same in nature as previously documented angina; and a known history of CAD (including prior MI). [3] Atypical presentations need to be considered in the elderly, diabetics and women.
At the primary care level, the Marburg Heart Score has been shown to have excellent negative predictive value (Table 2 ). Based only on variables acquired on history and examination, it is an easytoapply clinical prediction rule. [4] 
Physical examination
All patients presenting with acute chest pain should undergo a thorough physical examination. In ACS, the cardiac examination is often unremarkable, but specific attention should be paid to the vital signs (pulse and BP), features of heart failure, and auscultation precordial murmurs and rubs. The presence of transient mitral regurgitation, hypotension, diaphoresis, pulmonary oedema, crackles or signs of extracardiac vascular disease is highly suggestive of ACS. ACS is less likely if the presenting chest pain is reproducible by chest palpation. [3] Examination of the respiratory system should exclude 
12-lead ECG
Patients presenting with acute chest pain should have a 12lead ECG performed and interpreted within 10 minutes of first medical contact. If the initial ECG is nondiagnostic but the diagnosis of ACS is highly suspected, serial ECGs should be performed (at 3 hours, 6 hours, 9 hours and 24 hours, or on recurrence of symptoms), including ECGs with additional leads for evaluation of the posteriorlateral myocardial wall V7 V8 V9 or V3R V4R V5R. ACS diagnostic features on the ECG include ST elevation, ST depression, Twave inversion, and new or presumed new left bundle branch block. ECG features suggesting pericarditis include saddleshaped ST elevation not confined to an anatomical location, with PR depression in V2 and PR elevation in aVR. ECG features suggestive of pulmonary embolism include tachycardia, features of right ventricular strain (Twave inversion V1 V3 with either right axis deviation or tall R in V1) and the typical SIQIIITIII pattern.
Cardiac biomarkers
Cardiac biomarkers reflect myocardial cell injury, the hallmark of MI. Pathophysiologically, MI results from ischaemia sufficient to cause cell death, with the release of cellular proteins and enzymes. Cardiac troponins I and T have been shown to be the most sensitive indicators of cardiac injury, as well as being predictors for short and longterm outcomes as regards death and MI. [5] The introduction of highsensitivity troponin (hsTc) assays have improved rapid rule out MI, and the confirmation of nonST elevation MI (NSTEMI). [6] It is important to understand that the increased sensitivity of the test results in lower specificity. To this end, the universal classification of MI was revised in 2012, acknowledging that for practical purposes, the diagnosis of ST elevation MI (STEMI) is made in the correct clinical setting with the appropriate ECG changes, and that MI without ST elevation (NSTEMI) requires positive biomarkers (Table 3) . If serial biomarkers are negative, this implies no MI has occurred, but the patient may still require treatment for unstable angina. In addition, positive biomarkers may reflect myocardial injury secondary to non coronary causes -usually as a result of imbalance between myocardial oxygen supply and demand -and should therefore be interpreted in the clinical context of the presentation. [7] 
CXR
The CXR is helpful when pneumothorax or pneumonia, aortic dissection (wide mediastinum) or pulmonary embolism (oligaemia of lung fields or wedgeshaped infarcts) is suspected. If, on the basis of the ECG, ACS is suspected, the urgency of obtaining a CXR should be relegated and implementation of management plans prioritised.
Fig. 1. Chest pain algorithm (BP = blood pressure; GCS = Glasgow coma scale; ACS = acute coronary syndrome; hs-Tc = high-sensitivity troponin; GI = gastrointestinal; PCI = percutaneous coronary intervention; PE-CT = pulmonary embolism-computed tomography; STEMI = ST elevation myocardial infarction; NSTEMI = non-ST elevation myocardial infarction).
The management of ACSs
The clinical presentations of CAD include stable angina pectoris, silent ischaemia, unstable angina, MI, heart failure and sudden death. [8] ACSs result from acute destabilisation of coronary athe roma with resultant complete or subtotal thrombotic coronary occlusion. Ischaemic discomfort or chest pain is experienced because of reduction in blood flow to the myocardium.
STEMI Pathophysiology and initial diagnosis
Plaque disruption exposes thrombogenic substances, resulting in intracoronary thrombus formation. Local anticoagulant production is increased and, if successful, will result in thrombus resolution and arrest of the infarction. However, if complete arterial occlusion occurs, myocardial ischaemia followed by infarction results, producing the typical ST elevation seen on the 12lead ECG. Diagnostic patterns of ST elevation vary depending on which epicardial vessel is involved (Fig. 2) .
Immediate management
The optimal management of STEMI patients includes providing the fastest, safest, most effective method of reperfusion therapy available, i.e. primary percutaneous coronary intervention (PPCI) or fibrinolysis, while simultaneously initiating essential adjunct ther pies and monitoring (Fig. 3) . Unless contraindicated, all patients should receive antiplatelet therapy (aspirin with P2Y 12 inhibitors such as ticagrelor, prasugrel or clopidogrel) and anticoagulation (unfractionated or lowmolecularweight heparins (LMWHs) dosed to body weight). Patients should be connected to a cardiac monitor capable of cardioversion and transcutaneous pacing. Oxygen should be administered if the patient is hypoxic, and opioids for pain relief, breathlessness and anxiety are essential. [9] Prehospital logistics of care The lack of a formal STEMI referral network for both public and private sectors makes decisions regarding reperfusion therapy challenging, and often impedes the rapid administration of reperfusion therapy. [10] Important timeframes that govern timely STEMI care are outlined in Fig. 4 . Prehospital logistics and patient practitioner education should aim to reduce delays from time of symptom onset to definitive reperfusion. [9, 11] Reperfusion therapy This includes PPCI, fibrinolysis and pharmacoinvasive strategies. Selecting the most appro priate reperfusion strategy depends on three key factors: the time delay from symptom onset to first medical contact; availability; and clinical factors that may favour one strategy over the other.
Patients presenting within 12 hours of onset of symptoms (or since worse exacer bation) As a general guide, STEMI patients present ing to PCIcapable facilities should be offered PPCI (preferably within 60 min utes). If there is an anticipated delay of >120 minutes from the time of first medical contact, fibrinolysis should be administered. Patients presenting to [12] Fibrinolysis and pharmaco-invasive strategies In most subSaharan countries, access to PPCIcapable facilities is limited. Fibrino lysis is therefore the first choice reperfusion therapy. Clear contraindications to fibrino lysis need to be identified during the initial assessment (Table 4) . Alteplase (tPA) with concomitant heparin was shown to be more effective than streptokinase (one fewer death per 100 patients treated, at the expense of three additional strokes).
Tenectaplase is equivalent to accelerated tPA for 30day mortality (with lower rate of bleeding). [13, 14] Nonpatientrelated factors when considering choice of fibrinolysis include cost, ease of administration and administration in hospital or before being admitted.
Pharmacoinvasive management refers to the combination of fibrinolysis and angio graphy, with a view to PCI of the culprit lesion. Patients who have had successful fibrinolysis can be referred to a PCI capable centre for routine angiography and PCI within 24 hours of completing fibrinolysis. This strategy has been shown to reduce recurrent MI and urgent revascularisation for recurrent ACSs, and is currently a very attractive option in South African (SA) clinical settings. [15] Patients presenting after 12 hours of symptom onset (or since worse exacerbation) Beyond 12 hours, fibrinolysis is far less effective than PPCI, while still carrying the risk of bleeding. Decisions regarding reperfusion should therefore be on an individual basis. Patients with persistent myocardial ischaemia, hypotension, haemodynamic instability or ventricular arrhyth mias should be considered for referral for angiography and PCI. Stable patients should receive antiplatelet therapy and anticoagulation with unfractionated heparins or LMWHs. [12] Failed fibrinolysis The 12lead ECG should be repeated 60 (tPA) 90 (streptokinase) minutes after fibrinolysis to assess therapeutic success. Failed fibrinolysis is indicated by failure of the ST elevation to reduce by >50% with or without persistent myocardial ischaemia. These patients do not benefit from repeat fibrinolysis, and should be considered for urgent rescue PCI, ideally within 12 hours. [12] 
NSTEMI and unstable angina Pathophysiology and initial diagnosis
The pathophysiology of most NSTEMIs involves the rupture of a vulnerable athero matous plaque with subsequent throm bus forma tion, leading to reduced blood flow and ischaemia, with or without MI (NSTEMI or unstable angina (UA), respectively).
The diagnosis is confirmed by the presence of prolonged (>20 minutes) ischaemic chest pain, newonset Canadian Class II or III angina, acute deterioration of stable chronic angina or angina following a recent MI, and the absence of ST elevation on the 12lead ECG. Atypical complaints (including silent ischaemia, epigastric pain, indigestion and dyspnoea) can occur in older patients (>75 years), women and patients with diabetes, chronic kidney disease or dementia. In these settings, STT wave abnormalities on ECG should prompt rapid ruleout or rulein of ACS using hsTc assays (Fig. 5) .
Immediate management and risk stratification
The immediate care of UA and NSTEMI patients involves two key steps: (i) risk stra tification using validated ischaemia and bleeding prediction tools before deciding on pharmacological and invasive management strategies; and (ii) the administration of evidencebased therapies. If there are no contraindications, a patient with a suspected diagnosis of ACS should receive antiplatelet therapy (aspirin and clopidogrel), anti coagu lation therapy (unfractionated heparins or LMWHs, or indirect factor Xa inhibitors (fondaparinux)), and antiischaemic agents (βblockers, or calcium channel blockers and nitrates).
Validated ischaemic risk prediction scores (Thrombolysis in MI (TIMI) Risk Score and the Global Registry of Acute Coronary Events (GRACE) Risk Score) use demographic, clinical, ECG and biochemical variables to estimate the short, intermediate and long term prognosis related to the current presentation ( Table 5 ). The validated CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of ACC/AHA guidelines)bleeding score combines eight predictors of major bleeding, allowing a physician to estimate the baseline risk of inhospital major bleeding, therefore complementing ischaemic risk prediction tools. These scores are readily available as applications on smartphones and tablets, making them easy to use in daily practice. Patients with intermediate to highrisk scores should be considered for invasive management, and advanced for coronary angiography with a view to revascularisation. Independent of risk scores, patients with significant rise or fall of troponin levels, dynamic ECG changes and ongoing ischaemia should be considered for invasive management.
Timing of angiography and intervention
Highrisk patients benefit from revasculari sation therapy. Patients with ongoing ischae mia, acute heart failure, lifethreatening ventricular arrhythmias or haemodynamic instability should be considered for immediate intervention regardless of biomarkers and ECG changes. Patients with highrisk scores who have clinically stabilised should be considered for angiography within 48 hours of admission. Lowrisk patients may be managed medically, or have coronary angiography deferred. These timelines are a guide and may differ based on the availability of PCI capable centres.
Hospitalisation and discharge
All ACS patients should be managed in a highcare setting, specifically for the rapid identification and management of haemo dynamic (cardiogenic shock) and arrhyth mic (ventricular tachycardia and fibrillation) complications, as well as bleeding (access site or secondary to fibrinolysis) and recurrent infarction. ECG monitoring and bed rest should continue for at least 24 hours after successful reperfusion and symptom resolution. Chronic medications that offer mortality benefit should be introduced while in hospi tal (unless contraindicated). Dual anti plate let therapy should be continued for 1 year, unless there are specific reasons to stop sooner. The introduction of βblockers, reninangiotensin system inhibitors, angio tensinconverting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) or aldosterone antagonists) and statins should be specific to the individual, rather than introduced as a routine 'cocktail' . The early introduction of highdose HMGCoA reductase inhibitors (statins) is also associated with improved survival and reduced morbidity. Beta blockers should be provided to all patients within 24 hours unless there is evidence of haemodynamic compromise, congestive heart failure or bradyarrhythmias (such as heart block). Patients with anterior MI, evidence of heart failure or depressed left ventricular systolic function should receive ACEIs or ARBs, plus an aldosterone antagonist. Lifestyle and risk factor modification including smoking cessation, diet, physical activity and BP control is essential. [9] Patients who require surgical revascularisation should be discussed with a combined heart team (interventional cardiologist, clinical cardio logist and cardiothoracic surgeon) regarding the optimal timing of surgery (inpatient v. elective readmission).
ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV in all leads other than leads V2 -V3 where the following cut-points apply: ≥0.2 mV in men ≥40 years; ≥0.25 mV in men <40 years; ≥0.15 mV in women Anterior STEMI: Typical ST elevation V2 -V5. 2A
Inferior STEMI: ST elevation in II, III, aVF. Also note the heart block.
2B
Lateral STEMI: ST elevation I and aVL, also V5 and V6. ST depression noted II, III, aVF, V1, V2, V3.
2C
Posterior STEMI: Deep ST depression V1 -V3 with prominent R waves V2, V3. When the ECG is viewed 'from behind' , ST elevation in V1, V2, V3 is clearly seen.
2D and E
Left bundle branch block (new or presumed new) in the setting of ACS. Eponymous signs like Cabrera's (notching in S-wave of V3 or V4) and Chapman's (notching in R-wave of I, aVL, or V6) have poor sensitivity, but reasonable specificity. Using the Sgarbossa criteria may be helpful.
2F
De Winter's sign (proximal LAD occlusion): 1 -3 mm upsloping ST segment depression at the J-point in leads V1 -V6 that continue into tall, positive symmetrical T-waves. QRS complexes are not wide (<120 ms), and there may be loss of precordial R-wave progression. May have ST elevation (1 -2 mm) in aVR. [19] 
2G
Atypical ECG presentations that deserve prompt management in patients with signs and symptoms of ongoing myocardial ischaemia include left bundle branch block, ventricular paced rhythms, isolated posterior MI, and ST elevation in lead aVR.
Fig. 2. ST elevation MI variations.
Less common ACS aetiologies
Infrequently, aetiologies other than ruptured atheroma result in ACS. Examples include coronary artery embolisation (in patients with atrial fibrillation, cardiomyopathy with ventricular clot or septic emboli from infective endocarditis), spontaneous coronary dissection (in patients with fibro muscular dysplasia, coronary vasculitis or thyrotoxicosis), coronary artery spasm (recreational drug use, de novo) and stressinduced cardiomyopathy (Takotsubo nonischaemic cardiomyopathy). Careful history and clinical exam ination can often identify these patients prior to definitive ACS care. Even so, the general principles of management are as outlined above.
ACSs in sub-Saharan Africa
ACSs are becoming increasingly prevalent in subSaharan Africa, with patients displaying similar myocardial risk factors to those of the developed world. [16, 17] There are limited data regarding ACSs in the SA context, with observational data suggesting that there are high intervention rates and frequent use of evidencebased pharmacological therapies with comparative outcomes when compared with international standards. [18] These data reflect mainly the care delivered in the private sector, and do not fully represent care from the public sector where resources are limited and timely presentation to healthcare facilities capable of managing ACSs is often delayed. [10, 16] Our current challenge is the provision of equal access and quality ACS care to all sectors of the SA population. This would entail reliance on the pharmacoinvasive strategy (routine and rescue) until there is adequate infrastructure expansion to accommodate the rollout of a comprehensive, organised, hubandspoke PPCI service. Initiatives such as the European Society of Cardiology 'StentforLife' project and planned national ACS registries could be the stepping stones to formalising management of ACSs on a national level. 
